Catalog No.
DHF19601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Target
BACE1, Memapsin-2, KIAA1149, Asp 2, Beta-site amyloid precursor protein cleaving enzyme 1, BACE, Beta-site APP cleaving enzyme 1, Beta-secretase 1, Aspartyl protease 2, ASP2, Membrane-associated aspartic protease 2, BACE1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P56817
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Genentech anti-BACE1
Soluble VCAM-1 may serve as a pharmacodynamic CSF marker to monitor BACE2 activity in non-human primates., PMID:40480341
Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease., PMID:40399225
Alzheimer's Is a Multiform Disease of Sustained Neuronal Integrated Stress Response Driven by the C99 Fragment Generated Independently of AβPP; Proteolytic Production of Aβ Is Suppressed in AD-Affected Neurons: Evolution of a Theory., PMID:40362488
Blockage of CCL3 with neutralizing antibody reduces neuroinflammation and reverses Alzheimer disease phenotypes., PMID:40268067
Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein., PMID:39885527
Magnesium-Phenolic Nanoeditor Refining Gliomatous T Cells for Metalloimmunotherapy., PMID:39701951
Autoantibodies to BACE1 promote Aβ accumulation and neurodegeneration in Alzheimer's disease., PMID:39448400
BACE Inhibitor Clinical Trials for Alzheimer's Disease., PMID:39422943
In-situ nanozyme catalytic amplification coupled with a universal antibody orientation strategy based electrochemical immunosensor for AD-related biomarker., PMID:39241336
The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling., PMID:38888964
Multicolor, Cell-Impermeable, and High Affinity BACE1 Inhibitor Probes Enable Superior Endogenous Staining and Imaging of Single Molecules., PMID:38842406
Identification and Analysis of Axolotl Homologs for Proteins Implicated in Human Neurodegenerative Proteinopathies., PMID:38540368
BV2 Membrane-Coated PEGylated-Liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy., PMID:38513154
Nicotinic acetylcholine receptor activation induces BACE1 transcription via the phosphorylation and stabilization of nuclear SP1., PMID:38110001
The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis., PMID:38020763
Platinum-alginate-chitosan nanobioconjugate decorated carbon backbone layered biosensor for highly sensitive and selective detection of BACE-1., PMID:37558026
Novel Human/Non-Human Primate Cross-Reactive Anti-Transferrin Receptor Nanobodies for Brain Delivery of Biologics., PMID:37376196
The Cleavage-Specific Tau 12A12mAb Exerts an Anti-Amyloidogenic Action by Modulating the Endocytic and Bioenergetic Pathways in Alzheimer's Disease Mouse Model., PMID:37298634
CDR3 Variants of the TXB2 Shuttle with Increased TfR1 Association Rate and Enhanced Brain Penetration., PMID:36986599
The Pursuit of the "Inside" of the Amyloid Hypothesis-Is C99 a Promising Therapeutic Target for Alzheimer's Disease?, PMID:36766796
Synaptogenic effect of APP-Swedish mutation in familial Alzheimer's disease., PMID:36260691
VHHs as tools for therapeutic protein delivery to the central nervous system., PMID:36192747
The metabolism of human soluble amyloid precursor protein isoforms is quantifiable by a stable isotope labeling-tandem mass spectrometry method., PMID:36056033
A proof of concept for targeting the PrPC - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer., PMID:35962130
Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer's Disease Therapy., PMID:35889246
Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules., PMID:35841881
The Cell Adhesion Molecule L1 Interacts with Methyl CpG Binding Protein 2 via Its Intracellular Domain., PMID:35408913
Electrochemical Detection of Alzheimer's Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide., PMID:35402415
AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model., PMID:35352880
The neuronal-specific isoform of BIN1 regulates β-secretase cleavage of APP and Aβ generation in a RIN3-dependent manner., PMID:35241726
An Essential Role for Alzheimer's-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis., PMID:35216328
BACE1 Overexpression Reduces SH-SY5Y Cell Viability Through a Mechanism Distinct from Amyloid-β Peptide Accumulation: Beta Prime-Mediated Competitive Depletion of sAβPPα., PMID:35180123
Self-Assembly of Superquenched Gold Nanoparticle Nanosensors for Lighting up BACE-1 in Live Cells., PMID:34739230
Novel Insight in Idiopathic Normal Pressure Hydrocephalus (iNPH) Biomarker Discovery in CSF., PMID:34360799
An Overview of β-Amyloid Cleaving Enzyme 1 (BACE1) in Alzheimer's Disease Therapy: Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor., PMID:34102967
11C-PiB and 124I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention., PMID:34088777
Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice., PMID:33848635
Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains., PMID:33848613
Dynamic Docking Using Multicanonical Molecular Dynamics: Simulating Complex Formation at the Atomistic Level., PMID:33759128
HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis., PMID:33667517
Ameliorating Ribosylation-Induced Amyloid-β Pathology by Berberine via Inhibiting mTOR/p70S6K Signaling., PMID:33361598
Scope of β-Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition., PMID:33073981
Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys., PMID:32461332
Synaptic Vesicle Protein 2B Negatively Regulates the Amyloidogenic Processing of AβPP as a Novel Interaction Partner of BACE1., PMID:32280101
Mouse brain proteomics establishes MDGA1 and CACHD1 as in vivo substrates of the Alzheimer protease BACE1., PMID:31908000
Mapping pathogenic processes contributing to neurodegeneration in Drosophila models of Alzheimer's disease., PMID:31823504
Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ., PMID:31787113
Protective effects of BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities in Alzheimer's disease., PMID:31595293
Functional selection of protease inhibitory antibodies., PMID:31363054
Characterization of Cerebrospinal Fluid BACE1 Species., PMID:31290061
For research use only. Not for human or drug use.
